grant
Developing a NAMPT activator for Alzheimer’s disease
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 15 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AD dementiaAD modelAccelerationAgeAgingAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimer's disease modelAlzheimer's disease patientAlzheimer's patientAlzheimers DementiaAnimal ModelAnimal Models and Related StudiesAnimalsAssayBindingBioassayBiological AssayBiological MarkersBlood SerumBody TissuesBrainBrain Nervous SystemCell BodyCellsChemicalsChemistryChronologyClinicalClinical TrialsCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalDataData SetDependenceDevelopment PlansDiseaseDisorderDisturbance in cognitionDoseEarly-Stage Clinical TrialsEncephalonEnzyme GeneEnzymesExhibitsFutureGoalsHumanIND FilingIND applicationIND packageIND submissionImpaired cognitionInduced pluripotent stem cell derived human neuronIntermediary MetabolismInvestigational New Drug ApplicationInvestigatorsLate Onset Alzheimer DiseaseLeadLegal patentLibrariesLigand BindingMetabolic ProcessesMetabolismMiceMice MammalsModelingModern ManMolecular InteractionMurineMusNMN pyrophosphorylaseNerve CellsNerve DegenerationNerve UnitNeural CellNeurocyteNeuron DegenerationNeuronsNutraceuticalPatentsPathway interactionsPatientsPb elementPhase 1 Clinical TrialsPhase I Clinical TrialsPopulationPre-Clinical ModelPreclinical ModelsPreclinical TestingPrimary Senile Degenerative DementiaQualifyingResearch PersonnelResearchersRisk FactorsRouteSeriesSerumSodium ChlorideTechnologyTestingTherapeutic IndexTissuesToxicologyValidationage associatedage associated declineage correlatedage dependentage dependent declineage linkedage relatedage related declineage reversalage specificaged brainagesaging brainaging reversalalleviate age relatedalleviate agingalzheimer modelameliorating agingbio-markersbiologic markerbiomarkerblood-based biomarkerblood-based markerclinical candidatecognitive dysfunctioncognitive functioncognitive losscommercial scale manufacturingcounter age relatedcounter agingcounteract age relatedcounteract agingdecline with agedrug developmentdrug discoveryexperienceheavy metal Pbheavy metal leadhiPSC-derived neuronshuman iPSC-derived sensory neuronhuman induced pluripotent stem cell derived sensory neuronhuman subjectiPSC-derived human neuronimprovedin vivoinducible pluripotent stem cell derived human neuroninducible pluripotent stem cell derived human sensory neuroninnovateinnovationinnovativelate onset alzheimerlead optimizationmanufacturemanufacturing ramp-upmanufacturing scale-upmild cognitive disordermild cognitive impairmentmodel of animalmouse modelmurine modelneural degenerationneurodegenerationneurodegenerativeneurological degenerationneuronalneuronal degenerationneurons differentiated from human induced pluripotent stem cellsnicotinamide phosphoribosyltransferasenovelpathwaypatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepharmacologicphase 1 evaluationphase 1 testingphase I evaluationphase I protocolphase I testingpre-clinicalpre-clinical efficacypre-clinical testingpreclinicalpreclinical efficacypreventpreventingprimary degenerative dementiaprogramsreverse agereverse agingreverse aging effectsreversible agingsaltscale upscale up batchscale up productionscreeningscreeningssenile dementia of the Alzheimer typesmall moleculetargeted biomarkerupscale manufacturinguptakevalidations
Description preview
Currently there are no therapies that can slow or reverse the cognitive decline seen in late-onset Alzheimer's
disease (LOAD). The single greatest risk factor for this condition is chronological age and as the global population
ages, the number of AD cases is expected to continue to rapidly increase. This age-dependent association has
led many to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click